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Biomarkers based on alterations in molecular and biochemical parameters may be useful in
chemical risk assessment for establishing the presence of an exposure, ranking relative risks
among exposed individuals, and estimating risks at low levels of exposure. Because it is unlikely
that the relation between toxic responses and the degree of alteration in the biomarker is
equivalent at all doses, quantification of risks at low levels is not necessarily more accurate using
these biomarkers for extrapolation. The application of response biomarkers for risk evaluation at
low levels of exposure is discussed in relation to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a
compound that causes induction of cytochromes CYP1Al and CYP1A2 in liver and other tissues.
CYP1A1 induction in liver increases monotonically with TCDD dosage; however, several of the
dose-response curves for hepatic effects of TCDD are U-shaped. The U-shaped dose-response
curve for hepatic tumor promotion appears to result because the integrated toxicologic response
depends on multiple underlying processes-mitosuppression, toxicity, and cell proliferation-each
of which has a different dose-response relationship with respect to TCDD. Although
dose-response relationships for the biomarkers are not expected to duplicate the complex shapes
seen with the integrated responses, measurements and pharmacodynamic modeling of the
changes in these molecular and biochemical parameters can still be useful for obtaining an upper-
bound risk estimate at low levels of exposure. Environ Health Perspect 106(Suppl 1:349-355
(1998). http.//ehpnetl.niehs.nih.gov/docs/1998/Suppl-1/349-355andersen/abstract.html
Key words: exposure biomarkers, response biomarkers, dose-response relationship, 2,3,7,8-
tetrachlorodibenzo-p-dioxin, TCDD, response curves, U-shaped curves, markers of tumor
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Introduction
Epidemiologic studies in human populations
are expected to be more relevant for
human risk assessments than the results of
animal toxicity studies. However, because
ofconfounding factors related to concur-
rent exposures to other chemicals, differ-
ences in individual lifestyles, difficulties in
accurately reconstructing exposures, and
the small sizes of most cohorts, few epi-
demiologic studies provide results that
unambiguously determine risks to humans
at low levels ofexposure. Thus, most con-
temporary risk assessments are based on
results from animal studies, in which it is
possible to control the exposure conditions
and expose animals to high doses ofovertly
toxic compounds.
In these cases, accurate estimation of
risks to human health posed by low-level
exposure to potentially toxic compounds
requires knowledge of the dose-response
relationship over a broad range of expo-
sures in the animal species. Unfortunately,
dose-response curves that define risks in
animals at low response rates are almost
nonexistent and in some cases may be
impossible to obtain. For toxic responses
with measurable background rates, such as
cancer and teratogenesis, it is difficult to
assess the significance of small increases
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above background response rates. These
studies only infrequently resolve differences
of response in the 1 in 20 to 1 in 100
range. When evaluating impaired function
such as reproductive competence, the nat-
ural variability in a healthy population of
measures ofeffect such as numbers oflive
births per litter greatly restrict accurate
assessment of low-level response rates
related to chemical exposures.
It may be possible to extend dose-
response curves to lower levels ofexposure
based on theoretical knowledge of the
mechanisms of toxicity by using so-called
biologically based models or by measuring
precursor biochemical or molecular events
directly involved in the sequence ofevents
leading to toxicity states. Proposed revised
carcinogen risk assessment guidelines (1)
discuss the use ofthese precursor events to
extend the dose-response curve to low
levels ofexposure and the role of biologi-
cally based models in cancer risk assess-
ment. Precursor events should be causally
related to toxicity to be useful in risk
assessment. A precursor response linked
mechanistically to toxicity is equivalent to
a biomarker ofresponse.
Biomarkers in RiskAssessment
Biomarkers are used to indicate that an
individual has been exposed to a toxic
chemical (exposure biomarkers) or that an
individual is at some risk oftoxicity because
of the exposure (response biomarkers).
Biomarkers of exposure include the pres-
ence ofthe compound or a specific metabo-
lite in blood or tissues or the presence of
macromolecular reaction products such as
hemoglobin adducts, which are not related
causally to any adverse outcome. Blood
cholinesterase inhibition by organophos-
phate insecticides is considered a bio-
marker ofexposure because the inhibition
ofthis enzymatic activity is not believed to
be involved directly in the neurotoxicity of
these compounds. These exposure bio-
markers can be important in epidemio-
logic studies for stratifying individuals
according to intensity of exposure rather
than relying on analysis ofwork practices
or lifestyle factors in creating categories of
exposure intensities.
With DNA-reactive carcinogenic
compounds, response biomarkers include
the presence of chemical-related DNA
adducts and the identification ofspecific
mutations in oncogenes. With compounds
that serve as tumor promoters, exposure
Environmental Health Perspectives d Vol 106, Supplement 1 * February 1998 349ANDERSEN AND BARTON
may lead to altered regulation ofgrowth
regulatory genes or to recurrent toxicity
with concomitant reparative hyperplasia.
With either DNA-reactive or indirect-acting
carcinogens, the various response biomark-
ers can be viewed in either qualitative or
quantitative fashion.
Ifthere is no evidence ofan increase in
response biomarkers, there should be no
increase in expected risk from a toxic com-
pound in target populations. This applica-
tion provides a qualitative argument ofthe
relationship between the biomarker and the
presumed risk. However, based on the
statistical power ofthe test measurement
there is still some level of increase in the
biomarker and therefore some level of
increased risk that cannot be evaluated
based directly on the measurements. A
more difficult question involves the quanti-
tative relationship between the intensity of
the biomarker in the organism and the risk
of overt toxicity. To use these precursor
events in quantitative risk estimation for
low-level exposures, it is necessary to under-
stand the relationship between these
precursor changes and toxic responses over
the full dose range of interest. This paper,
using experience with 2,3,7,8-tetra-
chlorodibenzo-p-dioxin (TCDD) as an
example, examines the advantages and
disadvantages ofusing response biomarkers
to estimate dose-response relationships
quantitatively at low levels ofexposures.
Response Markers
with TCDD
TCDD is a member ofthe class ofpoly-
chlorinated dibenzo-p-dioxins (PCDDs).
Many of these PCDDs, especially those
with lateral chlorine substituents, produce a
characteristic constellation ofbiologic effects
in experimental animals; these effects
indude liver cancer in female rats (2,3), ter-
atogenicity (4) and immunotoxicity in mice
(5), and reproductive/developmental effects
in adult male and female rats exposed in
utero (6,7). Cancer is a relatively high dose
effect compared to these other responses.
TCDD Biomarkers
In addition to these overt toxic effects,
TCDD also produces changes at the mole-
cular and biochemical levels, including
increases in the concentrations ofa number
of enzymes involved in cellular metabo-
lism. The most extensively studied effect is
the induction of two cytochrome P450
enzymes, CYPlAl andCYP1A2, in multiple
animal species. The toxicologic and enzyme-
inducing effects ofTCDD appear to be
initiated bythe interaction ofTCDD with a
cellular protein-the aryl hydrocarbon
(Ah) receptor.
Our understanding ofthe mechanisms
ofTCDD interactions with the Ah recep-
tor are based primarily on studies of
CYPlAI induction by TCDD. The inac-
tive Ah receptor consists ofan aggregate of
several proteins (8).
Binding TCDD to the Ah receptor
aggregate leads to dissociation ofthe Ah
receptor from the aggregate and dimeriza-
tion of the Ah-TCDD complex with
another protein, the aryl hydrocarbon
nuclear transferase (arnt). Both the Ah pro-
tein (9) and arnt (10) are n-helix-loop-
helix DNA binding proteins. The
heterodimer formed from these two pro-
teins has a high affinity for specific DNA
response elements found upstream from
the CYPIAJ gene. For other proteins, such
as CYP1A2, gene transcription is increased
by the Ah-TCDD complex even though
there is no CYPlAI-like response element
upstream from this gene (11).
OtherHepaticResponseMarkers
TCDD also has other effects in the liver
intermediate between these biochemical
responses and overt carcinogenicity. Pitot et
al. (12) evaluated the ability ofTCDD to
promote growth ofaltered enzyme foci in
livers offemale rats initiated by a regimen of
two-thirds partial hepatectomy (PH) fol-
lowed byadose of10 mgdiethylnitrosamine
(DEN) per kg body weight. TCDD was a
potent promoter in this study, causing an
increase in the number offoci per volume
and in the amount ofthe liver occupied by
foci at dailydoses of100 ngTCDD/kg. The
dose-response curve for these effects
appeared to be U-shaped (Figure 1).
Van Bergelen et al. (13) found that
TCDD treatment increased the concentra-
tions ofporphyrins in the liver and that
this increase correlated well with the induc-
tion ofCYP1A2. Mechanistically, this cor-
relation may arise because the metabolism
of uroporphyrinogen III to uroporphyrin
III is catalyzed by CYP1A2 (14). TCDD
also increases the proliferation rate ofhepa-
tocytes and induces toxicity, defined as
cytoplasmic vacuolation, fatty changes, bile
duct hyperplasia, and pigment in Kupfer
cells (15). Stinchcombe et al. (16) found
that apoptotic rates of the cells in altered
foci staining positively for glutathione
S-transferase (GST) produced by TCDD
treatment were much lower than the apop-
totic rates measured in these foci in the
absence ofTCDD. Any of these various
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Figure 1. Effects of TCDD treatment on the growth of
altered hepatic foci (AHF) in female rats. Rats were
administered single doses of DEN as an initiating
agent 24 following 70% PH. TCDD was dosed every 2
weeks to provide an average daily dose as specified on
the x-axis. The AHF represent any and all foci forthree
markers-y-glutamyltranspeptidase, adenosine
triphosphatase, and glucose 6-phosphatase. Data from
Pitot et al. (12). The doses used correspond to the daily
doses used in the original cancer bioassay (2). In the
original bioassay (2) the incidence of cancer at the
three doses-0.001, 0.01, and 0.1 pg/kg/day-were
1/86, 0/50, 2/50, and 11/49, respectively. In the Pitot
et al. study (12) the control rats were sacrificed at 8
months, while the treated rats were sacrificed at 6
months (36). These differences diminish the U-shaped
behavior for volume occupied by AHF; they are not
expected to affect the overall shape of the curve for
AHF numbers in the liver.
processes may be regarded as precursor
steps to the development ofliver tumors.
SpecificityandSensitivity
Two important concepts in evaluating the
utility of any particular biomarker are
whether the biomarker can be associated
uniquely with a specific exposure (speci-
ficity) and whether it is clearly elevated at
even low levels of exposure (sensitivity).
The presence ofTCDD in tissues is a spe-
cific measurement of TCDD exposure
because TCDD is not an endogenous com-
pound in plants or animals. All the
response markers-induction, cell prolifer-
ation, toxicity, and altered apoptosis-are
nonspecific, i.e., they can be associated
with other xenobiotics or with natural
processes within the animal. Although all
these response markers are nonspecific,
some markers of induction of CYPIA
enzymes, for example, are much more sen-
sitive than others, cell proliferation and
toxicity, for example.
The most widely used marker in experi-
mental animals for exposure to PCDDs
and similar compounds is the induction of
the CYPIA family cytochromes. This
sensitive biomarker is not specific to
TCDD or even to halogenated poly-
aromatic compounds. Other PCDDs,
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chlorinated dibenzofurans, some PCBs,
and some natural products such as poly-
aromatic hydrocarbons also induce these
proteins. Within a human population,
increased CYPlAI is a measure ofexposure
to awide variety ofcompounds that activate
theAh-receptor aggregate.
Characterizing the
Biomarker Dose Response
Induction ofCYPlAI mRNA by TCDD
has been studied to assess responses at low
levels ofexposure in rats (17). The utility of
CYPlAI as a response marker at low levels
ofexposure requires accurate characterization
ofthe dose-response relationship between
induction and hepatic concentrations
ofTCDD.
Bars and Elcombe (18) first noted that
CYPIA enzyme induction by TCDD was
heterogeneous over the liver acinus.
Tritscher et al. (19) reported induction in
livers ofrats treated for 3 months. At lower
doses (3.5 and 10.7 ng TCDD/kg/day)
induction occurred in the centrilobular
region and progressively moved outward to
the mid-zonal and then the periportal areas
as dose increased up to 125 ng/kg/day. In
addition, when the immunohistochemically
stained slides were evaluated closely, cells
were found to be either fully induced or in a
basal state, i.e., there was a sharp boundary
between areas ofinduced cells and areas with
no induced cells (18). Thus, TCDD appears
to cause a shift in the state ofhepatocytes
from the basal noninduced phenotype to a
dioxin-activated phenotype in which
CYPlAI and CYP1A2 are fullyinduced.
Physiologically based pharmacokinetic
models for TCDD that included gene
induction were developed in the late 1980s
and early 1990s (20-24). These initial
CYP1A family induction models did not
consider heterogeneous induction in evalu-
ating the dose response for this molecular
marker ofthe effects ofTCDD on the liver.
These earlier models were successful in
explaining the induction averaged over the
whole liver but required alteration to simul-
taneously describe the nonlinear induction
ofCYPlAI mRNAbyTCDD (17).
Models ofRegionalInduction
These pharmacokinetic and gene induction
models recently were extended to consider
regional effects together with the obser-
vation of the sharp boundary between
induced and noninduced regions (25,26).
In common with their single liver compart-
ment precursors, these more recent models
still described TCDD activity based on the
presumption of an increased rate of tran-
scription of CYPIA mRNA related to the
occupancy of dioxin response elements
(DREs) on DNA by the Ah-TCDD com-
plex. The relationship between Ah-TCDD
and the rate oftranscription was:
rate = basal rate
maximum ratexAh-TCDD"
Ah-TCDD +Kdi& [1]
To account for regional induction with
sharp boundaries, the presumed binding
affinity ofDREs for the Ah-TCDD com-
plex (Kdi) were varied among five compart-
ments in the liver. The five compartments
(Figure 2) were defined geometrically as
a hexagonal acinar structure (25). The
model was capable ofsimulating available
data on total induction of mRNA and
CYPIA family proteins and on the regional
patterns ofinduction when the Hill coeffi-
cients were large (4 or greater) and the Kdi
values varied by a factor of3 between com-
partments. This parameterization of the
multicompartment liver model predicted a
variation of 81 in the effective binding
affinity over the five compartments.
The requirement of a large n-value
indicates a steep, highly nonlinear dose-
response relationship for induction in both
the observed and low-dose regions. In the
published analysis by Andersen et al. (26)
the dissociation constant in the centrilo-
bular region (the most sensitive region of
the liver for CYP1A induction) was
estimated to be 0.1 1 nM Ah-TCDD for
induction of CYP1A2. With the n-value
equal to 4, the proportionate response for
CYP induction in the centrilobular region
at a 10-fold lower concentration of
Ah-TCDD complex (0.011 nM) would be
reduced to 1 x 104. The response rate for
the centrilobular hepatocytes would fall to
one dioxin-activated cell per 1,000,000 nor-
mal cells when the concentration of the
Ah-TCDD complex in this compartment is
the Ah-TCDD complex-DNA dissociation
constant divided by 31.
Thus, risks associated with events that
were directly dependent on induction and
activation ofcells to a dioxin-responding
phenotype as obligate precursor event would
be minimal (1 in 106) ifthe receptor com-
plex concentration fell below 0.000355 nM.
Similar conclusions regarding receptor-
ligand concentrations associated with mini-
mal risks would also be valid for other
hepatic enzyme inducers with heterogeneous
patterns ofinduction in which individual
cells appear to be either in the normal state
or fully induced. These compounds include
phenobarbital, peroxisomal proliferators, and
avariety ofdioxinlike compounds, including
dibenzofurans and coplanar PCBs.
A
Figure 2. A schematic representation of the surfaces of hexagonal acinar structures within the liver in the geo-
metric liver model used to predict regional induction characteristics with TCDD. The most recent physiologically
based pharmacokinetic (PBPK) models for TCDD subdivide the liver acinus into five compartments based on con-
centric regions within the acinus (25,26). This geometric model (Al allows prediction of regional induction (1) by
assuming different binding characteristics ofTCDD with DNA response elements in each region. Estimates oftotal
induction in a region are estimated and compared to maximally induced levels. The proportion induction is then
used to calculate a color intensity for the region (B). To obtain sharp boundaries with some fully induced regions
(the two centrilobular zones) and other noninduced regions (the two periportal zones), the Hill coefficients in the
induction equations in the PBPK models must be 4 or greater. Any comprehensive model of hepatic induction by
most CYP450 inducers should account forregional effects aswell as effects averaged overthe entire liver.
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Biomarkers and
Low-dose Risks
Enzyme induction indicates that hepatocytes
have responded to TCDD exposure and
provides a measure ofthe number ofhepa-
tocytes in the new dioxin-activated state.
Induction alone does not appear to be a
toxic response or to be directly related to
toxicity, although the induction of por-
phyria associated with increased CYP1A2
maybe an exception.
The hepatocarcinogenicity of dioxin
appears instead to result from the sponta-
neous appearance of mutated cells that
have reduced responsiveness to the growth
regulatory control affecting normal cells. In
the presence ofTCDD, mutated cells grow
to be identifiable clones. As the clones
increase in size, the opportunities for sub-
sequent mutations to more aggressive cell
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Figure 3. Labeling index in normal hepatocytes in
female Sprague-Dawley rats atthe end of a 90-day ini-
tiation/promotion study. (A)The rats in this study were
the initiation controls. They were treated with TCDD
but not initiated with DEN. In these rats labeling was
not homogeneously observed throughout the acinus. At
10, 35, and 125 ng TCDD/kg/day, labeling was
reported predominantly in the periportal (pp) area. (B)
In this study rats were initiated with a necrotizing dose
of DEN (175 mg/kg). In these rats labeling occurred
randomly (r) throughout the liver acinus. The r and pp
notations atthe higher doses indicate that the majority
of animals in these groups had proliferation reported
as r or pp. Data from Maronpot et al. (15).
types also increase. If the probability of
mutation or the cell proliferation rates were
simple functions ofthe cells recruited into
the dioxin-activated state, it would be pos-
sible to estimate the dose-response curve
for all levels of exposure from measure-
ments ofCYPlA1 induction. The evidence
below, however, suggests that no simple
relationship exists between carcinogenicity
and the extent ofenzyme induction.
Cell-labling Ind&/Regional
Proliferation
Fox et al. (27) found that rats treated for 2
weeks with TCDD at doses leading to tis-
sue concentrations of150 ng/g tissue exhib-
ited marked shifts in patterns ofhepatocyte
proliferation within the acinar structures of
the liver. In control rats proliferation
occurred randomly throughout the acinus.
With TCDD treatment, the proliferation
was primarily periportal, with reduced
proliferation rates in the rest of the liver.
Maronpot et al. (15) found that in
TCDD-treated rats proliferating cells were
preferentially located in the periportal areas
of the acinus at doses of 10, 35, and 125
ng/kg/day. The authors also noted a
decrease in labeling index in DEN-initiated
livers treated with 3.5 ng TCDD/kg/day,
which suggested inhibition ofcell prolifera-
tion compared to that in controls at this
relativelylowdose ofTCDD (Figure 3).
Bauman et al. (28) studied the effect of
TCDD on the regeneration of liver after
PH. Twenty-four hours after PH, 61% of
the hepatocytes in control animals were in
the cell cycle, i.e., cells identified by stain-
ing techniques to be in either G1, S, G2,
or M phase ofthe cell cycle. With TCDD
only 41% of the hepatocytes were in the
cell cycle at a comparable time after PH.
These results indicate that one ofthe func-
tional responses ofthe liver to TCDD is a
decrease in responsiveness ofhepatocytes to
mitogenic stimulation. The authors also
found a decreased response ofTCDD-
treated livers to mitostimulation by lead
nitrate. In general, the body of research
with TCDD indicated mitosuppression
and shift ofproliferation to the periportal
region at low doses, whereas cell prolifera-
tion throughout the liver and toxicity
occur at higher doses.
Mechanisms ofPromotion
andCarcinogenicity
Two proposals have been made to account
for the potency ofTCDD as a tumor pro-
moter. Portier et al. (29) and Moolgavkar
et al. (30) developed models ofpromotion
in which DEN treatment produced a single
type ofmutated cell. All clones observed at
each dose ofTCDD were believed to be
derived from that single cell type. Based on
this biologic structure for the nature ofthe
mutated cell population, the initiation-
promotion data were consistent with a
model in which TCDD acted as an initia-
tor to increase the production ofmutated
cells over time during the study. This con-
clusion is difficult to reconcile with the fact
that TCDD has been tested for mutagenic-
ity in multiple in vivo and in vitro test sys-
tems. With two exceptions (31,32) all
mutagenicity tests were negative.
In contrast, Andersen et al. (33) and
Conolly and Andersen (34) evaluated an
alternative model for interpreting these ini-
tiation-promotion results with TCDD. In
their model DEN initiation produces two
cell types (A and B) capable ofbecoming
clones ofenzyme-altered foci in the livers.
One ofthese cell types, A, responds to the
negative growth environment associated
with TCDD treatment. The net growth
rate for this cell type, given bythe birth rate
minus the death rate (aA-PA), decreases
with increasing TCDD exposure. Most
clones observed in DEN controls in the
absence ofTCDD treatment are expected
to be derived from these A cells. The sec-
ond type ofcell, B, is unresponsive to the
mitoinhibitory environment associated with
TCDD treatment. For these cells gB-1PB
increases with increasing concentrations of
TCDD. At the high exposure concentra-
tions in the initiation-promotion studies,
the observed clones are derived primarily
from these B cells. This two-cell model is
consistent with the observed U-shaped
dose-response curves, explains TCDD pro-
motion without assuming a mutational
component to the formation ofthe clones
over time, and is consistent with a mitoin-
hibitory action ofTCDD on normal cells
that is absent in the B-cell clones (34).
Dose Dependencies
of Response Mechanisms
The data on hepatic effects ofTCDD are
consistent with three distinct ranges of
behavior (Table 1). Lower doses (1-5
ng/kg/day in rats) affect a small portion of
the hepatocytes (up to about 10%) and
appear to have little effect on either cell
proliferation rates or toxicity. There may be
limited mitosuppression in this region
(Figure 3). Moderate doses (10-30
ng/kg/day) produce induction ofbetween
30 and 50% ofthe cells. There is evidence
ofmitoinhibition with little enhancement
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Table 1. Dose dependence oftoxic mechanisms underlying TCDD carcinogenesis.
Characterization of responsea
Effect Dose region Dose region 11 Dose region IlIl
Portion of liver induced -5-30% >30% >70%
Hepatocyte proliferation Primarily inhibition Little overall effect Primarily stimulation
Toxicity/oxidative stress Minimal Moderate Severe
&Characterization obtained from studies on TCDD initiation/promotion reported by Maronpot et al. ( 15) and
Tritscher etal. (19).
ofproliferation rates, although there is a
more periportal pattern ofproliferation.
Finally, at higher doses (35-125 ng/kg/day)
proliferation, toxicity, and the persistence
ofmitoinhibition combine to increase the
number ofrisk factors for carcinogenicity.
The interaction ofmultiple risk factors at
the higher doses indicates that cancer risk
should decrease disproportionately with
dosage as animals move toward the low-
dose range. The proliferation may be
related to high-dose toxicity associated
with a role ofCYP1A2 induction, which
leads to porphyria. Mitosuppression also
seems to increase with increasing dosages.
If these multiple factors interact, cancer
risks should increase as a power ofdose.
Based on the gene induction model, we
calculated the Ah-TCDD concentration
expected to be associated with a 1 in 106
level ofinduction in the centrilobular com-
partment (3.5 x 104 nM). Because the dose
response for carcinogenicity is expected to
be nonlinear with contributions from mul-
tiple factors, the biomarker dose-response
curve at low levels ofexposure would pro-
vide a conservative estimate ofrisk. 'When
the biomarker falls to an expected response
level of 1 per 106, the carcinogenic risk
would be expected to be much below this
level. Although molecular parameters may
be poor predictors of actual risk, these
markers could be used to provide a conserv-
ative bound. This more limited quantitative
use ofthe biomarker, although perhaps dis-
appointing from a mechanistic perspective,
at least avoids low-dose extrapolation based
on nothing more than policy.
Hormesis Unraveled
The observed production of a mito-
inhibitory growth environment in the
liver appears to represent an adaptive
response. Although beneficial for mainte-
nance of the correct size of the liver and
probably for maintenance of the correct
proportion of normal and dioxin-acti-
vated cells, this adaptive response when
maintained continuously throughout the
life ofthe animal selects for the growth of
precursor lesions with mutations in critical
growth regulatory genes. In this scenario,
which is consistent with experiences with
other tumor promoters (35), the ongoing
toxicity with TCDD in the face of the
homeostatic, mitoinhibited environment
sets the stage for a higher probability of
conversion ofcells with growth regulatory
lesions to more aggressive carcinoma.
Several lines of evidence support
U-shaped dose-response curves for hepatic
effects ofTCDD, including initiation/
promotion (12), carcinogenicity (2), and
cell labeling (15). The downward sloping
portion of these curves appears to be in
the range where mitosuppression occurs.
This mitoinhibition appears to protect the
liver from carcinoma production. It
would be misleading, however, to call this
low-dose protection.
The overall U-shaped curve appears to be
associated with regions ofthe dose-response
regime in which different effects ofdioxin
predominate over others. At high doses the
combination ofproliferation, toxicity, and
mitoinhibition acts to enhance carcino-
genicity. At lower doses mitoinhibition,
acting in the absence oftoxicity and prolif-
erative responses, appears to moderate cell
proliferation and reduce the incidence of
foci production and tumors relative to
those in controls. This region is not a dose
region where all effects of TCDD are
expected to be beneficial. It is a region in
which the mitoinhibition in liver predomi-
nates over other effects. In other tissues the
TCDD-related effects associated with these
altered cell growth characteristics may be
associated with other toxic effects. One
caution from this evaluation of the possi-
bility of U-shaped curves with TCDD
relates to the definitions ofboth hormesis
and low levels ofexposure. Low levels of
exposure, in this context, simply refer to
levels below those that have overt increases
in toxic responses. The dose that causes a
low-level response in one tissue may be
associated with much higher levels of
response in a second tissue. Hormesis is an
empirical definition based on observing
complex dose-response curves for specific
toxic responses. When we realize that the
pathogenicities of most toxic responses are
composites ofmultiple effects ofthe chem-
ical on the organ system, it is easy to see
that complex curves may arise from differ-
ential dose-response relationships for the
contributing mechanisms ofpathogenesis.
Summary
Molecular and biochemical biomarkers of
response are qualitatively useful in assessing
whether risk can be attributed to an expo-
sure by assessing whether an increase in the
biomarker has occurred. Among groups of
exposed individuals, the magnitude of a
biomarker in any one individual can be
used to broadly categorize exposure and to
rank the degree ofrisk forvarious individu-
als. However, it is difficult to estimate low-
dose risks based solely on the intensity of
biochemical and molecular markers of
response. Most biomarkers are not propor-
tionally related to the toxic response, and
the underlying mechanisms oftoxicity con-
tributing to pathogenesis are themselves
complexly related to dose. Therefore, it is
unlikely that simple relationships will
emerge between early molecular and bio-
chemical parameters and toxic responses at
low levels ofexposure.
Biochemical and molecular parameters
that are specific and sensitive may be useful
for identifying doses below which increases
in biomarker are not statistically signifi-
cant. Experimental measurements alone
cannot unequivocally establish a total lack
ofresponse because ofthe statistical power
ofthe test systems. Biologically based phar-
macodynamic models such as that for
regional and cell-specific induction with
TCDD have the potential to provide char-
acterization ofthe functional relationships
between dose and the biomarker and may
increase our confidence in extending the
predictions ofthe dose-response relation-
ship for the biomarker to lower doses based
on mechanistic considerations. In contrast
to toxicity processes, molecular responses
such as CYPIA family induction are
simpler and depend on fewer biologic fac-
tors than toxic and carcinogenic sequelae.
Therefore, these models of low-level
increases in biomarkers are more likely to
be testable by experimental studies than
pharmacodynamic models of toxic
responses. Despite difficulties in equating
biomarker concentrations with specific
degrees ofrisk, estimation oflow-level risks
based on these biomarkers is likely to be
important in placing an upper bound on
risk if it is assumed that a direct relation
exists between the biomarker and toxicity.
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